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Trimetazidine dihydrochloride is an anti-anginal drug, which
possesses protective properties against ischemia inducing heart
damage. In this paper, a new procedure for liquid chromatographic
analysis was successfully developed, optimized, and applied in
assessment of trimetazidine dihydrochloride content and its
impurities, Y-145, Y-235, and Y-234 at most 1.0%, 0.2%, and
0.2%, respectively, in commercially available pharmaceutical
preparation containing 35 mg of trimetazidine dihydrochloride.
The retention behavior of trimetazidine dihydrochloride and its
impurities is investigated by using several stationary and mobile
phases to settle a simple, sensitive, and precise RP-HPLC method.
The separation conditions are optimized by DryLab 2000 Plus
Chromatography Optimization Software version 3.5.00.
Separations are performed on PurospherSTAR RP18 endcapped
(150 × 4.6 mm, 5 µm particle size) column at 20°C with UV
detection at 210 nm. The mobile phase composition is acetonitrile−
aqueous phase (10 mmol/L disodium hydrogenphosphate and
2 mmol/L sodium dihydrogen phosphate, pH 7.6) (30:70 v/v).
Afterwards, the method is validated; the important statistical
parameters for selectivity/specificity, linearity, precision, limit of
detection, and quantitation are defined. The recovery value of the
trimetazidine dihydrochloride is 98.06%, and the content of
impurities is 0.23% for Y-145, less than 0.02% for Y-235, and less
than 0.01% for Y-234. In addition, this method is used for
analyzing trimetazidine dihydrochloride and its impurities in
pharmaceuticals and bulk drug.
Introduction
Trimetazidine dihydrochloride, an anti–ischemic metabolic
agent, improves myocardial glucose utilization through the
inhibition of fatty acid oxidation, and it can be used as a
vasodilator in angina pectoris or ischemic heart disease (1,2).
The analyzed tablets contain 35 mg of trimetazidine dihy-
drochloride (1–[(2,3,4–trimethoxyphenyl)methyl]piperazine
dihydrochloride) and not more than 1.0% of Y-145 (4-(2,3,4-
Trimethoxybenzyl)-1-piperazinecarbaldehyde hydrochloride),
not more than 0.2% of Y-235 (2,3,4-trimethoxybenzylalcohol),
and not more than 0.2% of Y-234 (2,3,4-trimethoxybenzalde-
hyde) impurities, calculated to the content of trimetazidine dihy-
drochloride. Structures of trimetazidine dihydrochloride and its
impurities are shown in Figure 1.
In the present literature, there are no references dealing with
analysis of trimetazidine and its impurities. Spectrophotometric
determination of trimetazidine dihydrochloride in bulk drug and
solid dosage forms was developed (3), as well as first-derivative
430
Abstract
Computer–Assisted Optimization and 
Validation of LC Analysis of Trimetazidine
Dihydrochloride and Its Impurities
Mirjana B. Medenica1,*, Darko P. Ivanovic2, Igor B. Popovic3, Andjelija M. Malenovic2, and Biljana S. Jancic2
1Faculty of Pharmacy, Department of Physical Chemistry, Vojvode Stepe 450, 11000 Belgrade, Serbia and Montenegro; 2Faculty of Pharmacy,
Department of Drug Analysis, Vojvode Stepe 450, 11000 Belgrade, Serbia and Montenegro; 3Medicines and Medical Devices Agency of
Serbia, Vojvode Stepe 458, 11000 Belgrade, Serbia and Montenegro
Reproduction (photocopying) of editorial content of this journal is prohibited without publisher’s permission.
Journal of Chromatographic Science, Vol. 46, May/June 2008
* Author to whom correspondence should be addressed: email medenica@pharmacy.bg.ac.yu
Figure 1. Structures of trimetazidine dihydrochloride and its impurities
(Y-145, Y-234, and Y-235) 
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spectrophotometric method (4). Densitometric high-perfor-
mance thin-layer chromatographic method for analysis of
trimetazidine dihydrochloride, both as a bulk drug, and in appro-
priate formulations was reported (5). Analysis of trimetazidine in
presence of its degradation products inducted by different agents
like acid, hydrogeny peroxydi, etc. was acheived using a liquid
chromatography (LC) method (6). In addition, stripping square-
wave voltammetry at a glassy carbon electrode was also success-
fully applied to an assay of trimetazidine dihydrochloride in the
tablet dosage form (7). Many methods have been sought for car-
rying out pharmacokinetic studies and for assessing trimetazi-
dine bioequivalences of pharmaceutical formulations. The
plasma concentration of trimetazidine dihydrochloride was esti-
mated by both reversed-phase LC (8,9) and LC–mass spectrom-
etry (MS)–MS method (10,11).
The aim of this investigation was to define the optimal chro-
matographic conditions using software to optimize the simulta-
neous determination of trimetazidine and its impurities. In this
paper, computer simulation software (DryLab) was employed in
developing an LC method for separation of trimetazidine and its
three impurities. Then, the method was validated and linearity,
precision, limits of detection, and limit of quantitation were set-
tled. Finally, the optimized and validated method was applied to
assaying a pharmaceutical dosage form. 
Experimental
Reagents and samples
All reagents used were of an analytical grade. Acetonitrile-gra-
dient grade (Lab Scan, Ireland), water (HPLC grade,) disodium-
hydrogenphosphate (Merck, Darmstadt, Germany), and
sodium-dihydrogenphosphate (Merck) were used to prepare the
mobile phase. The tablets (Preductal MR, batch number:
3M3003) produced Les Laboratories Servier Industrie, France.
Working standards of trimetazidine dihydrochloride, Y-145, Y-
235, and Y-234 were obtained from the manufacturer.
Equipment and software
The chromatographic system, Hewlett Packard 1100 (Agilent,
Technologies, Germany), consisted of an HP 1100 pump (serial:
DE23912441), HP 1100 UV–vis detector (serial JP24019419), HP
ChemStation integrator, and HP autosampler 1100 (serial DE
23909987). The columns: Purospher® STAR C18 150 mm × 4.6
mm; LiChroCART C18 5 µm, 250 × 4.6 mm; Zorbax SB C18, 5 µm,
150 × 4.6 mm and Zorbax Eclipse XDB C8 5 µm, 150 × 4.6 mm
were used in the chromatographic investigation and separation.
The statistical software DryLab 2000 Plus Chromatography
Optimization Software version 3.5.00 (Molnar-Institut für ange-
wandte Chromatographie, Schneeglöckchenstrasse 47, D-10407
Berlin, Germany) was employed for the method optimization.
Standard solutions for linearity testing
The stock solutions were prepared by dissolving the working
standard substances in the mobile phase to obtain the concen-
tration of 0.1 mg/mL for trimetazidine dihydrochloride, 1.0
µg/mL for impurity Y-145, 0.2 µg/mL for impurities Y-234 and Y-
235. For the calibration curves, a series of seven solutions were
prepared in the concentration range from 0.01 mg/mL to 0.1
mg/mL for trimetazidine dihydrochloride; from 0.1 µg/mL to 1.0
µg/mL for Y-145, and from 0.02 µg/mL to 0.2 µg/mL for Y-235
and Y-234.
Laboratory mixtures
In order to justify the validity of the proposed method, the
solutions of trimetazidine, Y-145, Y-234, and Y-235 were made in
the concentration ratio corresponded to the content in tablets.
For quantitative analysis, three series with ten solutions for each
concentration were prepared (0.05 mg/mL, 0.06 mg/mL, and
0.07 mg/mL for trimetazidine dihydrochloride; 0.5 µg/mL, 0.6
µg/mL and 0.7 µg/mL for Y-145; 0.1 µg/mL, 0.12 µg/mL and 0.14
Table I. Chromatographic Parameters for Trimetazidine Dihydrochloride and its Impurities*
pH of the 
mobile phase 6.9 7.4 7.6 8.8
Parameters k' α Rs k' α Rs k' α Rs k' α Rs
Compound
Obtained with Dry Lab software
Trimetazidine 0.6 3.50 12.51 0.6 3.01 11.47 0.8 2.42 9.80 2.0 1.21 2.83
dihydrochloride
Y-235 2.0 1.45 5.64 2.0 1.47 5.91 2.0 1.5 6.22 2.4 1.25 3.65
Y-145 2.8 2.77 18.89 2.9 2.73 18.67 2.9 2.67 18.34 3.0 2.66 18.33
Y-234 7.9 7.8 7.8 7.9
Experimental Results
Trimetazidine 1.35 2.61 12.66 1.53 2.30 10.43 1.78 1.99 8.90 3.55 1.18 1.78
dihydrochloride
Y-235 3.52 1.37 5.97 3.53 1.40 6.55 3.54 1.43 7.31 4.19 1.22 2.34
Y-145 4.81 2.60 20.64 4.95 2.54 20.30 5.05 2.49 21.24 5.10 2.48 20.88
Y-234 12.53 12.57 12.55 12.66
* Abbreviations:  k' = Retention factor, α = Selectivity factor, and Rs = Resolution factor.
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µg/mL for Y-234 and Y-235) and injected into the column.
Sample solutions
Ten solutions in concentration of 0.06 mg/mL calculated to
trimetazidine dihydrochloride were prepared from homogenous
tablet mass according to the following procedure. The powered
tablet mass corresponds to 15 mg trimetazidine dihydrochloride
dissolved in volumetric flask of 25 mL with mobile phase and
placed into the ultrasonic bath for 40 min. After that, the solu-
tion was centrifuged at 4000 rpm (5 min) and then diluted with
mobile phase in ratio 1:10. The obtained solutions were injected
in the column using an autosampler.
Chromatographic conditions
Separations were performed on the Purospher STAR C18 (150
mm × 4.6 mm, 5 µm particle size) column at 20°C. The samples
were introduced using autosampler. Separation and
simultaneous determination of the trimetazidine dihydrochlo-
ride and impurities Y-145, Y-235, and Y-234 were performed
using the mobile phase, which consisted of 300 mL of
acetonitrile and 700 mL of aqueous phase, which contained 10
mmol/L disodium hydrogenphosphate and 2 mmol/L sodium
dihydrogenphosphate. The mobile phase was filtered through a
0.2 µm Millipore filter. The flow rate was 1.0 mL/min,
temperature of column 20°C, and injection volume 20 µL with
UV detection at 210 nm.
Results and Discussion
In the recent years, development of any chromatographic
method has always been followed by method optimization
because all the proposed methods should be simple and cheap as
much as possible and less time consuming. The general goal in
any optimization is to discover the conditions that produce the
best outputs. Method optimization could be done using the
experimental design (12–16), chemometrics (17–19), or dif-
ferent kinds of software like the DryLab (20–28).
Computer–assisted optimization employing specific software,
such as DryLab 2000 Plus Chromatography Optimization
Software version 3.5.00, proved to be quite a useful tool for opti-
mization in different types of chromatographic analysis. Either
chemometrics or software is used for method optimization. The
most important part, and at the same time the
starting point is the preliminary investigation.
It helps to recognize and select the chromato-
graphic factors that affect separation the most.
In the conventional separations, the retention
of analytes is related to their hydrophobicity.
For that reason, the starting point in the
method development was the analysis of chem-
ical structures of the investigated substances,
because the retention of the investigated sub-
stances could be predicted. Trimetazidine and
Y-145 as molecules possessing piperazine have
a basic character, and a bad peak shape in
reverse-phase chromatographic analysis was
expected. Difference in structure between them (Y-145 has a
formyl group on piperazine part) resulted in a different
lipophilicity of molecules, so in reversed-phase mode a longer
retention of Y-145 was expected. The other two impurities, Y-234
and Y-235, do not have a basic character because of the absence
of the piperazine part. The difference between them is at position
1, Y-235 has a formyl group and Y-234 has hydroxy–methyl
group. According to the structure and knowledge of the separa-
tion in the reverse-phase separation, Y-235 as more lipophilic
compound will have longer retention. So, this analytical
problem presents resolution of two structurally similar pairs of
substances, trimetazidine/Y-145 and Y-234/Y-235. This consider-
ation leads to a selection of non-polar columns (C8 and C18) for
preliminary experiments. Chromatographic behavior of
trimetazidine and its impurities was analyzed using a different
mobile and stationary phases.
Separation on C8 (Zorbax Eclipse XDB C8 5 µm, 150 × 4.6 mm)
column with mobile phases containing different ratio of
acetonitrile at pH lower than 5.0, resulted in coelution of
trimetazidine dihydrochloride with a peak of mobile phase.
There was no separation in pH range between 5.0 and 8.0. The
usage of the mobile phase with pH greater than 8.0 gave a bad
peak shape of the active compound. The addition of
triethylamine (TEA) had no influence on a peak symmetry of
trimetazidine dihydrochloride. Under these chromatographic
conditions, the resolution of the pair trimetazidine dihydrochlo-
ride/Y-145 had values less than 1 as well. Furthermore, the
separation on the C18 (LiChroCART C18 5 µm, 250 × 4.6 mm and
Zorbax SB C18, 5 µm, 150 × 4.6 mm ) was investigated. The
acetonitrile content in the mobile phase varied from 20% to 40%
with or without addition of TEA. The separation was not achieved
with these mobile phases. On C18 (PurospherSTAR RP18 end-
capped, 150 × 4.6 mm, 5 µm), the separation was performed with
acetonitrile–aqueous (from 20:80 v/v to 40:60 v/v) as a mobile
phases. Addition of sodium-dodecil sulphate in different
concentrations resulted in formation of ion pair with trimetazi-
dine dihydrochloride, and it led to the separation of the investi-
gated substances. However, a chromatographic peak for
trimetazidine dihydrochloride was asymmetrycal, and the
retention time was very long and unreproducible. The addition
of TEA resulted in better separation of the investigated
substances and the run time was significantly reduced. Better
results were not obtained with other types of ion pair reagents,
such as heptan-1-sulfonic acid and octan-1-sulfonic acid.
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Table II. The Important Parameters for the Calibration Curves*
Parameter Trimetazidine Y-145 Y-235 Y-234
dihydrochloride (mg/mL) (mg/mL) (mg/mL) (mg/mL)
Concentration 0.01 – 0.1 0.1 – 1.0 0.02 – 0.2 0.02 – 0.2
range
y = ax + b 94261x + 42.48 151.66x – 0.0598 177.35x + 0.299 88.4x – 0.26
r 0.9998 0.9999 0.9997 0.9994
Sb 57.94 0.62 0.27 0.20
ttab 0.931 0.123 1.399 1.696
* Abbreviations: r = Correlation Coefficient; Sb = Standard Deviation of the Intercept; ttab = 1.943 (p = 0.05).
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Variations of column temperature (from 25°C to 45°C) had no
influence on the separation. Since the best results were achieved
on this column, it was used for further investigations. Separation
and peak symmetry were significantly improved with mobile
phases containing acetonitrile and different ratio of disodium
hydrogenphosphate and sodium dihydrogenphosphate in the
aqueous phase. Retention times of the investigated substances
were shortened, but non-retention behavior of trimetazidine was
noticeable at lower values of pH. When an analyte is ionized, its
retention is strongly influenced with pH of the mobile phase.
Considering a trimetazidine basic character, it is in ionized form
in acidic solutions, so pH of the mobile phase is the most
important chromatographic factor which could affect its
behavior. Structurally similar Y-145 impurity is less basic
because of the presence of formyl group, which decreases the
basic character of piperazine part, and at the same time it is more
lipophilic and its retention is longer. According to the previously
mentioned, the pH interval from 6.0 to 8.0 was studied. In that
pH range, trimetazidine is in a molecular form, so its retention
must be longer than at lower values of pH.
In the method optimization, one factor was changed and the
other chromatographic factors were kept on constant level. In
this way, for optimization, a few experiments only are enough for
predicting a chromatographic behavior in a wide range of the
investigated factors. The pH of the aqueous phase was the factor,
which was extracted for analysis by the software as the most
important factor for chromatographic separation of the investi-
gated mixture. Moreover, in order to find the best conditions for
the separation, four different pH levels (6.9, 7.4, 7.6, and 8.8) of
aqueous phase were chosen as the most important factor, while
the other chromatographic factors (content of acetonitrile 30%
v/v, aqueous phase 10 mmol/L disodium hydrogenphosphate,
and 2 mmol/L sodium dihydrogenphosphate, temperature 20°C
and flow rate 1 mL/min) were constant. Resulting retention
times and peak areas are introduced in DryLab. The computer-
assisted optimization performed by the software using the
obtained experimental data as well as the column parameters
(diameter, particle size and pore diameter), the instrument
parameters (void volume: 1 mL, extra column volume and tem-
perature), a flow rate, and the composition of phosphate buffer.
According to the input parameters, the software gave a resolu-
tion map for the most critical pair in the separation (Y-235/Y-
145) shown in Figure 2 as well as predicted values for
chromatographic parameters (Table I).
The resolution map indicates that the proposed method is
robust within the pH range 7.6 ± 0.2 which was enabled by the
phosphate buffer in the mobile phase. The chromatographic
parameters obtained from DryLab, as well as the experimental
results (Table I), indicated that the optimal values for the reten-
tion time, selectivities, and resolutions would be gained with the
mobile phase containing acetonitrile–aqueous phase (10
mmol/L disodium hydrogenphosphate and 2 mmol/L sodium
dihydrogenphosphate, pH 7.6) (30:70).
Comparing the predicted results and experimental ones for
selectivity and resolution, a good agreement of corresponding
chromatographic parameters can be seen. Significant difference
between predicted values and values calculated from experi-
mental data for the retention factor is caused by a difference in
software calculation of t0 and experimental t0 value. Because of
that, the software is using resolution to produce resolution maps
for further preditions and optimal conditions setting.
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Figure 3. The chromatogram of trimetazidine dihydrochloride (tR = 2.792
min) and its impurities: Y-235 (tR = 4.54 min), Y-145 (tR = 6.05 min), and Y-
234 (tR = 13.56 min) in: A, laboratory mixture; B, tablets; (mobile phase: ace-
tonitrile–aqueous (10 mmol/L disodium hydrogenphosphate and 2 mmol/L
sodium dihydrogenphosphate, pH 7.6) (30:70 v/v); flow rate, 1.0 mL/min; UV
detection, 210 nm). 
Table III. LOD and LOQ
Compound LOQ* LOD*
(mg/mL) (mg/mL)
Trimetazidine 0.07 0.020
dihydrochloride
Y-145 0.02 0.005
Y-235 0.02 0.007
Y-234 0.04 0.001
* Experimentally determined values.
Figure 2. Resolution map for resolution between Y-235 and Y-145 obtained
by DryLab 2000 Plus Chromatography Optimization Software version 
3.5.00.
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After establishing the optimal conditions, the method was
submitted to the method validation (e.g., selectivity, linearity,
precision, limit of quantification and limit of detection were
determined). Furthermore, the assay was selective, and no sig-
nificant interfering peaks of the excipients were observed at the
retention time of trimetazidine dihydrochloride and its impuri-
ties. All the excipients were eluted at different times and they did
not interfere with analyzed compounds. The representative
chromatograms of the laboratory mixture and the corre-
sponding tablets are given in Figure 3.
In the concentration range from 0.01 mg/mL to 0.1 mg/mL for
trimetazidine dihydrochloride, from 0.1 µg/mL to 1.0 µg/mL for
Y-145, and from 0.02 µg/mL to 0.2 µg/mL for Y-234 and Y-235, a
linear relationship was obtained and the regression parameters
are given in Table II.
The linear relationship of the peak over the mentioned con-
centration range for trimetazidine dihydrochloride, Y-145, Y-
235, and Y-234 was obtained. Since the correlation coefficient for
the calibration curves of trimetazidine dihydrochloride and its
three investigated impurities was greater than 0.9994 and a sta-
tistical parameter (tb) calculated using Statistica 5 software was
lower than tabular value (ttab), it could be concluded that the cal-
ibration curves were within the linearity acceptance criteria.
For the quantitative analysis, it was important to define the
values of a limit of detection (LOD) and a limit of quantification
(LOQ) (Table III). The signal-to-noise ratio of 3:1 and 10:1 were
taken as LOD and LOQ, respectively and further confirmed by
taking dilutions from the secondary stock solution till the peak
area obtained has 3 (for LOD) and 10 (for LOQ) fold then the
standard deviation of six determination. 
For the evaluation of method precision the important statis-
tical values, such as standard deviation (S) and coefficient of vari-
ation (CV), as well as good recoveries, were calculated. Standard
deviation and coefficient of variation have the small-required
values (Table IV).
For the evaluation of the method precision,
the important statistical values such as standard
deviation (S) and coefficient of variation (CV), as
well as good recoveries were calculated. The
standard deviation and the coefficient of varia-
tion had small, required values.
After the evaluation, the proposed method was
applied for the determination of the content of
trimetazidine dihydrochloride, Y-145, Y-234 and
Y-235 in the Preductal tablets available on the
pharmaceutical market. The content of
trimetazidine dihydrochloride was 98.06%, and
the level of impurities met the given require-
ments well (e.g., Y-145 0.23%, level of Y-235 and
Y-234 was under the LOD).
The results of the assay for trimetazidine dihy-
drochloride and its impurities in tablets are
given in Table V.
Conclusion
The computer–assisted optimization em-
ploying the specific software was used in order to
obtain the most appropriate chromatographic
conditions for the analysis of trimetazidine dihy-
drochloride and its impurities. This paper pre-
sents a useful improvement in drug analysis
offering a simpler and quicker way to obtain the
optimal separation conditions. The evaluation of
the proposed method proved its selectivity, preci-
sion and accuracy, and so its applicability to the
qualitative and quantitative analysis of the inves-
tigated substances in the corresponding tablets
in the presence of excipients. The proposed
method was rapid and sensitive, and represents a
significant improve-ment in chromatographic
analysis and application of this technique for a
drug analysis purposes.
Table IV. Precision of the Proposed LC Method
CV R
Compound Injected Found (%) (%)
Trimetazidine 0.05 0.0515 ± 0.0003* 0.66 103.1
dihydrochloride 0.06 0.0603 ± 0.0002 0.37 100.5
(mg/mL) 0.07 0.0701 ± 0.0003 0.42 100.2
Y-145 0.5 0.494 ± 0.005 1.03 98.87
(mg/mL) 0.6 0.594 ± 0.003 0.45 98.98
0.7 0.699 ± 0.002 0.35 99.90
Y-235 0.10 0.098 ± 0.001 1.12 98.29
(mg/mL) 0.12 0.1182 ± 0.0008 0.64 98.49
0.14 0.1392 ± 0.0007 0.50 98.40
Y-234 0.10 0.099± 0.002 1.95 99.66
(mg/mL) 0.12 0.118 ± 0.001 0.74 98.79
0.14 0.139 ± 0.001 0.85 99.06
* Standard Deviation (n = 10).
Table V. Quantitative Analyses
Compound Taken Found Found CV R
(mg/mL) (mg/mL) (mg/tbl) (%) (%)
Trimetazidine 0.06 0.0588 ± 0.0005* 34.32 0.8 98.06
hydrochloride
Compound MAC† Found Found CV
(mg/mL) (mg/mL) (%) (%)
Y-145 0.6 0.227 ± 0.006 0.23 2.52
Y-235 0.12 Less than LOD‡ –
Y-234 0.12 Less than LOD‡ –
* Standard Deviation, S (n = 10).
† MAC: Maximum allowed content.
‡ LOD: Limit of Detection of impurity (see Table III).
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